Topical Therapy

DRUG3 trials

Sponsors

Hillel Yaffe Medical Center, University of California, Irvine, Amgen

Conditions

Plaque PsoriasisPsoriasisTinea Pedis

Phase 3

A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy

CompletedNCT03930186

AmgenPlaque Psoriasis

Start: 2019-06-17End: 2020-09-25Updated: 2022-01-20

Unknown Phase

Safety and Efficacy of a Novel Topical Therapy for Tinea Pedis (Athlete's Foot)

Hillel Yaffe Medical CenterTinea Pedis

Start: 2009-04-30Target: 100Updated: 2009-02-24

Evaluation of Vitamin D Levels in Psoriasis Patients

WithdrawnNCT01903317

University of California, IrvinePsoriasis

Start: 2013-06-30End: 2015-07-31Updated: 2024-05-08

Related Papers

Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from PROMINENT

Dermatology and Therapy2024-05-27

Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study

Dermatology and Therapy2022-06-0112 citations